NCT05487170 - A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

June 1, 2025

Study Completion Date

September 1, 2025

Conditions

Advanced Solid TumorDLBCL

Interventions

DRUG

RNK05047

RNK05047 is a chaperone-mediated protein degrader administered as IV infusion once weekly for 3 consecutive weeks in a 4-week cycle (no treatment in the fourth week).

Trial Locations (5)

10065

COMPLETED

Weill Cornell - NY Presbyterian Hospital, New York

30322

COMPLETED

Emory University Winship Cancer Institute, Atlanta

40202

COMPLETED

Norton Cancer Institute, Louisville

100021

RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

100142

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors

lead

Ranok Therapeutics (Hangzhou) Co., Ltd.

INDUSTRY